Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21340817 | 1.00 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL21332796 | 1.00 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL21332922 | 0.85 | CTSK (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL20118769 | 0.85 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL21341197 | 0.85 | CTSK (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL21332920 | 0.85 | CTSK (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL20118765 | 0.84 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL22364357 | 0.84 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL22364358 | 0.84 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL18075260 | 0.82 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221459-B2 | Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides | MEDIVIR AB (SE) | 2025-02-11 | — | — | US | disclosed |
| EP-3762394-A1 | CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENECYCLOPROPANE NUCLEOTIDES | Medivir Aktiebolag (SE) | 2021-01-13 | — | — | EP | disclosed |
| US-20200399295-A1 | CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENECYCLOPROPANE NUCLEOTIDES | MEDIVIR AB (SE) | 2020-12-24 | — | — | US | disclosed |
| WO-2019172835-A1 | CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENECYCLOPROPANE NUCLEOTIDES | MEDIVIR AKTIEBOLAG (SE) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221459-B2 | Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides | PNP, NUDT1, TYMP | CTSK 3925/4885CTSS 2840/4885CA1 4111/4885 |
| US-20200399295-A1 | CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENECYCLOPROPANE NUCLEOTIDES | PNP, NUDT1, TYMP | CTSK 3925/4885CTSS 2840/4885CA1 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.